Latest:
Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of Life
The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Adrienne Phillips, MD, MPH
Latest:
Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL
Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.
Agnieszka Janus, MD, PhD
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell Leukemia
Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Agustin A. Garcia, MD
Latest:
Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer
The evaluation of noncytotoxic agents for
the treatment of epithelial ovarian cancer
has produced encouraging findings in
recent months, which has led to the approval of
new agents with novel mechanisms of action
and continuing studies into many more potential
therapies.
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD, is a tenured senior member of the Departments of Cutaneous Oncology and Immunology, the director of Cutaneous Clinical and Translational Research, and the leader of the Neoadjuvant and Adjuvant Translational Science Program at the Moffitt Cancer Center and Research Institute; as well as a professor of oncologic sciences at the University of South Florida Morsani College of Medicine
Latest:
Dr Tarhini on the Rationale for Studying Vidutolimod Plus Pembrolizumab in Melanoma
Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.
Ahmed A. Hussein Aly, MD, PhD
Latest:
TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?
Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.
Ahmed O. Kaseb, MD
Latest:
Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC
Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.
Ahmet Dogan, MD, PhD
Latest:
Dr. Dogan on Updated WHO Classifications in DLBCL
Ahmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).
Aileen M. Soper, BA
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management
Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of
available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial
relationship between payers and oncologists through a collaborative model.
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, is a gastrointestinal medical oncologist at the MedStar Health Lombardi Cancer Center
Latest:
Dr He on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable/Metastatic HCC
Aiwu Ruth He, MD, PhD, discusses the significance of data from the CheckMate 9DW trial evaluating frontline nivolumab plus ipilimumab in metastatic HCC.